Willis Towers Watson (WLTW) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
5 Nov, 2025Executive summary
Achieved 5% organic revenue growth and 150 basis points of adjusted operating margin expansion in Q2 2025, with adjusted EPS up 20% year-over-year to $2.86 and diluted EPS up 144% to $3.32.
Net income rose 135% to $332 million for the quarter, driven by cost reductions and operational efficiencies.
Strategic focus on performance acceleration, efficiency, and portfolio optimization, with technology and AI investments delivering measurable efficiency gains.
Returned $500 million to shareholders via share repurchases and paid $91 million in dividends in Q2 2025.
Completed divestiture of TRANZACT on December 31, 2024, impacting year-over-year revenue comparisons and creating a $1.14 headwind to adjusted EPS for 2025.
Financial highlights
Q2 2025 revenue was $2.26 billion, flat year-over-year; organic revenue up 5%.
Net income for Q2 2025 was $332 million, up from $142 million in Q2 2024; diluted EPS was $3.32.
Adjusted operating margin reached 18.5% in Q2 2025, up 150 basis points year-over-year.
Adjusted EBITDA for Q2 2025 was $470 million (20.8% margin), up from $445 million (19.6%).
Free cash flow for the first half of 2025 was $217 million, down from $305 million in the prior year due to higher incentive costs, tax payments, and the absence of TRANZACT inflows.
Outlook and guidance
On track to deliver full-year 2025 guidance: mid-single-digit organic growth, adjusted operating margin expansion, adjusted EPS growth, and free cash flow margin improvement.
Expecting ~$1.5 billion in share repurchases in 2025, subject to market conditions and M&A opportunities.
Risk & Broking expected to achieve mid to high single-digit organic growth and ~100 basis points of average annual margin expansion over the next three years.
Health, Wealth & Career expected to maintain mid-single-digit revenue growth and incremental margin expansion.
Foreign currency expected to provide a $0.05 tailwind to adjusted diluted EPS in 2025.
Latest events from Willis Towers Watson
- Organic growth and margin expansion drove strong results despite divestiture impacts.WLTW
Q4 20253 Feb 2026 - Q2 2024 delivered 6% organic growth, margin expansion, and raised 2024 guidance.WLTW
Q2 20242 Feb 2026 - Q3 saw 6% revenue growth, margin gains, and a $1.67B loss from TRANZACT sale charges.WLTW
Q3 202417 Jan 2026 - Sustained organic growth and margin expansion driven by innovation, efficiency, and portfolio optimization.WLTW
CMD 202412 Jan 2026 - 5% organic growth, margin gains, $473M savings, and $1.5B buyback planned for 2025.WLTW
Q4 20248 Jan 2026 - $1.3B acquisition leverages advanced tech and talent for $35M in synergies and U.S. growth.WLTW
M&A Announcement10 Dec 2025 - 2025 AGM to vote on directors, auditors, executive pay, share issuance, and pre-emption rights.WLTW
Proxy Filing1 Dec 2025 - Annual meeting covers director elections, pay, and auditor ratification.WLTW
Proxy Filing1 Dec 2025 - 5% organic growth and margin expansion offset TRANZACT sale; net income up 23%.WLTW
Q1 20251 Dec 2025